Sep. 3 at 8:44 PM
$PFE @walfofwallstreet
“Medicus Pharma is paying the drugmaker
$12 million upfront for rights to PF-08046031, which targets melanotransferrin, or CD228, a protein highly expressed in melanoma and several other solid tumors. Medicus also owes Pfizer another
$15 million on Sept. 2, 2027, the first anniversary of the deal, according to a filing with the Securities and Exchange Commission.
Should the ADC make it to market, Pfizer would be eligible for royalties and could also earn more than
$1 billion in development, regulatory and sales milestone payments. The Big Pharma also pitched in
$2 million to help Medicus get started on its new cancer prospect.’
https://www.fiercebiotech.com/biotech/pfizer-offloads-scrapped-seagen-adc-medicus-pharma-1b-deal
LT